ZTZhenzhen Tu

Zhenzhen Tu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhenzhen Tu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Haisheng Zhou

    Department of Biochemistry and Molecular Biology, Anhui Medical University, Hefei, China

    2 shared publications
  • Siping Zhang

    Department of Dermatology, Anhui Medical University Affiliated Provincial Hospital, Hefei, China

    2 shared publications
  • Wei Wei

    Department of Dermatology, Anhui Medical University Affiliated Provincial Hospital, Hefei, China

    2 shared publications
  • Chunlin Cai

    Department of Pathophysiology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China

    1 shared publication
  • Fanjun Zeng

    Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China

    1 shared publication
  • Fusheng Zhou

    Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, China; Institute of Dermatology, Anhui Medical University, Hefei, China

    1 shared publication

Latest Publications

  • Open Access

    IL-6 Up-Regulates Expression of LIM-Domain Only Protein 4 in Psoriatic Keratinocytes through Activation of the MEK/ERK/NF-κB Pathway

    by Zhenzhen Tu, Wei Wei, Fanjun Zeng, Wenwen Wang, Yuyan Zhang, Yintao Zhang, Fusheng Zhou, Chunlin Cai, Siping Zhang, Haisheng Zhou


  • Open Access

    Pro‐inflammatory cytokine IL‐6 regulates LMO4 expression in psoriatic keratinocytes via AKT/STAT3 pathway

    by Zhenzhen Tu, Wei Wei, Qiantong Xiang, Wenwen Wang, Siping Zhang, Haisheng Zhou

    The transcription factor LIM‐only protein 4 (LMO4) is overexpressed in the psoriatic epidermis and regulates keratinocyte proliferation and differentiation. High LMO4 expression levels are induced by interleukin‐23 (IL‐23) to activate the AKT/STAT3 signaling pathway. Interleukin‐6 (IL‐6) is mainly involved in regulating T cell functions and development in patients with psoriasis. However, whether LMO4 expression is regulated by IL‐6 remains unclear. Therefore, the purpose of this study is to explore the role and molecular mechanisms of IL‐6 in regulating LMO4 expression. The interleukin‐6 (IL‐6) levels in human plasma were determined using a chemiluminescence immunoassay system. A psoriasis‐like mouse model was established using imiquimod induction. Epidermal keratinocytes (HaCaT) were cultured in defined keratinocyte‐serum‐free medium and stimulated by IL‐6 alone or with inhibitors. The proteins of interest were detected using western blot analysis, immunofluorescence, and immunohistochemistry. The 5‐ethynyl‐2′‐deoxyuridine assay was used to detect cell proliferation. The results revealed that IL‐6 levels were markedly increased in the plasma of patients with psoriasis, compared to healthy control. The high expression of LMO4 was consistent with high levels of IL‐6, p‐AKT, and p‐STAT3 in the lesions of both psoriasis patients and imiquimod‐induced psoriasis‐like mice. IL‐6 activates the AKT/STAT3 signaling pathway, followed by LMO4 high‐expression in HaCaT cells. IL‐6 induces HaCaT proliferation and differentiation via AKT/STAT3 signaling pathway activation. We think that the high expression of LMO4 in psoriatic keratinocytes requires IL‐6 to activate the AKT/STAT3 signaling pathway and leads to epidermal keratinocytes abnormal proliferation and differentiation.


  • Combined short‐ and long‐axis method for internal jugular vein catheterization in premature newborns: A randomized controlled trial

    by Wei Liu, Zhenzhen Tu, Lifei Liu, Yanzhe Tan

    Background Rapid central venous catheterization is critical for the rescue and perioperative management of premature infants requiring surgery. Ultrasound‐guided dynamic needle tip positioning (DNTP) has been widely used as a very effective technique, especially in paediatric vascular puncture and catheterization. However, for low‐weight premature newborns, central vein catheterization still poses greater difficulties for paediatricians and paediatric anaesthesiologists. This prospective randomized control study aimed to evaluate the efficacy of combined short‐ and long‐axis (CSLA) internal jugular vein catheterization for premature newborns in comparison with the DNTP technique. Methods A total of 90 premature newborns (gestational age n=45): the CSLA group and the DNTP group. We compared the first‐puncture success rate, total success rate, procedure time, number of needle passes, occurrence of complications and other outcome measures between the two groups. Results The two groups (n=45 per group) were similar in sex, gestational age, weight, mean arterial blood pressure, and vein‐related measurements of the internal jugular vein. Total success was achieved in 43 (95.6%) and 36 (80.0%) patients in the CSLA and DNTP groups, respectively. Compared with the DNTP group, the CSLA group showed a significantly higher first‐attempt success rate (71.1% vs. 46.7%, χ2 =5.5533, P=0.0184) and significantly fewer needle passes (1.0[1.0‐2.0] vs. 2.0[1.0‐3.0], χ2=‐2.6094, P=0.0091). There was no significant difference between the groups in the procedure time (368[304‐573] vs. 478[324‐79]s, Z=‐1.7690, P=0.0769). Complications occurred in both groups, but the incidence was significantly lower in the CSLA group than in the DNTP group (6.7% vs. 22.2%, χ2 =4.4056, P=0.0358). Conclusions Ultrasound‐guided internal jugular vein catheterization by the CSLA method is effective and safe. The CSLA method may be superior to the DNTP technique in premature newborns.


  • Therapeutic effect of the treatment for colorectal cancer with adenoviral vectors mediated estrogen receptor β gene therapy combined with thermotherapy

    by Zhenzhen Tu, Yuxiang Ma, Walter Akers, Samuel Achilefu, Yueqing Gu

    Our preliminary study on repressing colorectal tumors by recombinant adenoviruses (Ads) delivering the human ERβ gene (Ad-ERβ) has achieved positive result. In this study, hydrophobic fluorescent dyes ICG-Der-01 was entrapped into the N-succinyl-N′-octyl chitosan (SOC) micelles to form the near infrared absorbing dyes SOC-ICG-Der-01 and SOC-ICG-Der-01 mediated near infrared laser (SOC-ICG-Der-01/NIR) thermotherapy was combined with Ad-ERβ gene therapy to regress colon cancer in vivo. Firstly, the antitumor efficacies of SOC-ICG-Der-01/NIR thermotherapy were investigated on S180 ascites tumor-bearing mice. Results indicated that, the average tumor volume of SOC-ICG-Der-01/NIR group was the smallest among the three treatment groups. Then, thermotherapy with SOC-ICG-Der-01/NIR combined with Ad-ERβ gene therapy to treat HCT-116 colon cancer xenograft model was investigated. Further results demonstrated that, SOC-ICG-Der-01/NIR thermotherapy showed the significantly inhibitory efficiency compared with control group and Ad-ERβ enhanced the therapeutic effect of SOC-ICG-Der-01/NIR. These findings demonstrated that combined administration of Ad-ERβ with SOC-ICG-Der-01/NIR thermotherapy represents a promising colon cancer therapeutic strategy.